Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

426

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

July 31, 2010

Study Completion Date

August 31, 2010

Conditions
Colorectal Cancer
Interventions
DRUG

CPT-11 and TS-1

TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.

DRUG

CPT-11, 5-FU and l-LV

Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.

Trial Locations (1)

384-0301

Saku Central Hospital, Saku

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Daiichi Sankyo Co., Ltd.

INDUSTRY

lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT00284258 - Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer | Biotech Hunter | Biotech Hunter